ERVW-1 and Zika virus infectious disease: Following ZIKV infection, CCR3 or CCR5 antagonists also dramatically reduced the number of ZIKV-infected hBMECs (Fig. 6A) and expressed NS5 and Env proteins (Fig. 6B).